Ensuring the high quality of colonoscopies in colorectal cancer (CRC) screening is essential to reducing CRC. Recently, computer-aided detection systems (CADe) that use artificial intelligence have attracted much attention as potentially useful tools for improving lesion detection in colonoscopy. However, evidence on the efficacy of CADe in CRC screening is lacking. We have planned a multi-national, multi-center, randomized controlled trial in the Asia-Pacific region to assess whether colonoscopy with CADe (test method) yields higher lesion detection (primary endpoint: adenoma detection rate) than colonoscopy without CADe (standard method) in CRC screening populations. The study will include 1400 participants aged 50-79 years who are due to undergo colonoscopy for CRC screening, whether as a primary screening colonoscopy or following a positive fecal immunochemical test. If the efficacy of CADe is proven from this study, the use of CADe in colonoscopy for CRC screening will become standard, leading to improved CRC screening.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyaf043DOI Listing

Publication Analysis

Top Keywords

crc screening
24
randomized controlled
8
controlled trial
8
computer-aided detection
8
detection systems
8
colorectal cancer
8
screening
8
asia-pacific region
8
lesion detection
8
efficacy cade
8

Similar Publications

Background: The incidence of colorectal cancer (CRC) is rapidly increasing, and early detection plays a crucial role in improving the prognosis and survival rates of patients. This study aimed to assess the diagnostic ability of combined SDC2-KCNQ5-IKZF1 methylation levels in plasma for CRC detection.

Methods: A total of 92 patients were recruited from the Department of General Surgery at the Second Hospital of Hebei Medical University, including 56 CRC patients, 22 polyp and adenoma patients, and 14 healthy controls.

View Article and Find Full Text PDF

Background And Objective: Changweiqing (CWQ) is a Chinese herbal formula for the treatment of the gastrointestinal tract diseases, but its role in the treatment of colorectal cancer (CRC) has not been clarified. This study aimed to explore the molecular mechanism of CWQ in CRC treatment through bioinformatics analysis and network pharmacology.

Methods: Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and SwissTargetPrediction database were used to collect the bioactive components of CWQ.

View Article and Find Full Text PDF

Background: The presence of tumour-infiltrating lymphocytes (TILs) is a well-established prognostic biomarker across multiple cancer types, with higher TIL counts being associated with lower recurrence rates and improved patient survival. We aimed to examine whether an automated intraepithelial TIL (iTIL) assessment could stratify patients by risk, with the ability to generalise across independent patient cohorts, using routine H&E slides of colorectal cancer (CRC). To our knowledge, no other existing fully automated iTIL system has demonstrated this capability.

View Article and Find Full Text PDF

Investigating the PI3K/AKT/mTOR axis in Buzhong Yiqi Decoction's anti-colorectal cancer activity.

Sci Rep

March 2025

Department of Oncology and Hematology, Xijing 986 Hospital, No. 269 Youyi East Road, Beilin District, Xi'an, 710054, Shaanxi, China.

Buzhong Yiqi Decoction (BZYQD) is a traditional Chinese medicine renowned for its anti-colorectal cancer (CRC) properties. However, the bioactive components and mechanisms of BZYQD against CRC remain unknown. In this study, LC-MS was used to analyze the chemical composition of BZYQD.

View Article and Find Full Text PDF

Artificial Intelligence and Whole Slide Imaging, a new tool for the Microsatellite Instability prediction in Colorectal Cancer: friend or foe?

Crit Rev Oncol Hematol

March 2025

Division of Gastroenterology, Fondazione IRCCS - Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. Electronic address:

Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide. Despite advances in screening and treatment, CRC is heterogeneous and the response to therapy varies significantly, limiting personalized treatment options. Certain molecular biomarkers, including microsatellite instability (MSI), are critical in planning personalized treatment, although only a subset of patients may benefit.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!